Plain-English translation of NCT06277024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a combination of three treatments — candenizumab, lenvatinib, and a chemotherapy regimen called SOX — for people with advanced stomach cancer or cancer at the junction between the stomach and esophagus. The cancer must be a type called HER2 negative, and you should not have received chemotherapy or other systemic treatment for advanced disease before. Researchers want to see how well this medication combination works and how safe it is.
Advanced stomach cancer is a serious condition with limited treatment options. This trial is exploring whether combining these three medications together might help more patients respond to treatment and live longer than existing options.
You likely qualify if…
You likely don't qualify if…
You would receive the three-medication combination as your treatment for advanced stomach cancer. The trial will monitor how well the treatment works by measuring whether your cancer shrinks, how long you survive, and how your quality of life changes. Researchers will also carefully track any side effects you experience and may adjust your dose if needed. Throughout the study, you will have regular visits for blood tests, scans, and check-ins with your medical team.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China